Cocrystal Pharma (NASDAQ:COCP) Posts Earnings Results, Misses Estimates By $0.06 EPS

Cocrystal Pharma (NASDAQ:COCP) announced its earnings results on Thursday. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.06), FiscalAI reports.

Cocrystal Pharma Stock Down 1.3%

Cocrystal Pharma stock traded down $0.01 during trading hours on Thursday, reaching $1.10. 34,849 shares of the company’s stock were exchanged, compared to its average volume of 1,029,841. The firm’s 50 day simple moving average is $0.99 and its 200 day simple moving average is $1.10. Cocrystal Pharma has a twelve month low of $0.76 and a twelve month high of $2.67. The firm has a market capitalization of $15.24 million, a PE ratio of -1.51 and a beta of 1.43.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC bought a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.72% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.